Intuitive Surgical, Inc. ISRG
- Market cap
- $140.7B
- P/E
- 45.8×
Follow ISRG
Intuitive Surgical, Inc. (ISRG) Operating cash flow
Intuitive Surgical, Inc.'s operating cash flow for fiscal 2025 was $3.0B, up 25.5% from $2.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.7B. Over the past ten years it has ranged from $806.2M (fiscal 2015) to $3.0B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. Intuitive Surgical, Inc. ranks 2nd of 55 Medical Instruments & Supplies companies by operating cash flow.
Operating cash flow, annual
Annual
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $3.0B | 25.49% |
| FY2024 | $2.4B | 33.15% |
| FY2023 | $1.8B | 21.67% |
| FY2022 | $1.5B | (28.65%) |
| FY2021 | $2.1B | 40.72% |
| FY2020 | $1.5B | (7.10%) |
| FY2019 | $1.6B | 36.65% |
| FY2018 | $1.2B | 2.25% |
| FY2017 | $1.1B | 5.23% |
| FY2016 | $1.1B | 34.83% |
Quarterly
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $1.1B | 16.35% |
| Mar 2026 | $911.9M | 2.17% |
| Dec 2025 | $892.5M | 6.12% |
| Sep 2025 | $841.0M | 17.56% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BDX Becton, Dickinson and Company compare | $4.0B |
| ISRG Intuitive Surgical, Inc. | $3.7B |
| MDLN Medline Inc. compare | $3.1B |
| ALC Alcon compare | $2.3B |
| RMD ResMed Inc. compare | $1.8B |
| BAX Baxter International Inc. compare | $1.3B |
| WST West Pharmaceutical Services, Inc. compare | $662.2M |
| SOLV Solventum Corporation compare | $209.0M |
| RGEN Repligen Corporation compare | $134.9M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ISRG
- Revenue
- Net income
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement